Condition: Acute Myocardial Infarction of Anterior Wall · Left Ventricular Thrombus · Prophylaxis · Sponsor: National Institute of Cardiovascular Diseases, Pakistan
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
This description comes directly from the study's public registry record.
Abdul Hakeem, MD FACC FSCAI FASE · +92 3355554342 · ahakeem@gmail.com
Sabha Bhatti, MD FASE FASNC FACC · 608-772-3048 · drsabhabhatti@gmail.com
Always discuss trial participation with your own doctor first.
| NICVD Pakistan | Karachi, Sindh, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06742567